BiotechTube

Pembrolizumab

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Malignant Pleural Mesothelioma

Conditions

Advanced Malignant Pleural Mesothelioma

Trial Timeline

Feb 12, 2021 → Jul 25, 2023

NCT ID
NCT04166734

About Pembrolizumab

Pembrolizumab is a phase 1 stage product being developed by Merck for Advanced Malignant Pleural Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04166734. Target conditions include Advanced Malignant Pleural Mesothelioma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (20)

NCT IDPhaseStatus
NCT02083484Pre-clinicalCompleted
NCT07302347Phase 1/2Recruiting
NCT07089992Phase 2Recruiting
NCT07007273Phase 2Recruiting
NCT04569461Phase 2Withdrawn
NCT05815927Phase 3Recruiting
NCT05852223Phase 2Recruiting
NCT05879120Phase 2Withdrawn
NCT06004336Phase 2Recruiting
NCT05496036Phase 2Recruiting
NCT05131919Phase 2Active
NCT05197322Phase 2Recruiting
NCT05406713Phase 2Active
NCT05025813Phase 2Recruiting
NCT06413095Phase 1Completed
NCT05191472Phase 2Terminated
NCT05204160Phase 2Withdrawn
NCT04575961Phase 2Active
NCT04417166Phase 2Recruiting
NCT05188508Phase 2Recruiting

Competing Products

20 competing products in Advanced Malignant Pleural Mesothelioma

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85